198 related articles for article (PubMed ID: 28179297)
1. Cilengitide and Cetuximab Reduce Cytokine Production and Colony Formation of Head and Neck Squamous Cell Carcinoma Cells
Wichmann G; Cedra S; Schlegel D; Kolb M; Wiegand S; Boehm A; Hofer M; Dietz A
Anticancer Res; 2017 Feb; 37(2):521-527. PubMed ID: 28179297
[TBL] [Abstract][Full Text] [Related]
2. Stimulation by Monocyte Chemoattractant Protein-1 Modulates the Ex-vivo Colony Formation by Head and Neck Squamous Cell Carcinoma Cells.
Wichmann G; Körner C; Boehm A; Mozet C; Dietz A
Anticancer Res; 2015 Jul; 35(7):3917-24. PubMed ID: 26124338
[TBL] [Abstract][Full Text] [Related]
3. Reduced Cytokine Release in Ex Vivo Response to Cilengitide and Cetuximab Is a Marker for Improved Survival of Head and Neck Cancer Patients.
Cedra S; Wiegand S; Kolb M; Dietz A; Wichmann G
Cancers (Basel); 2017 Sep; 9(9):. PubMed ID: 28872582
[TBL] [Abstract][Full Text] [Related]
4. Cilengitide combined with cetuximab and platinum-based chemotherapy as first-line treatment in advanced non-small-cell lung cancer (NSCLC) patients: results of an open-label, randomized, controlled phase II study (CERTO).
Vansteenkiste J; Barlesi F; Waller CF; Bennouna J; Gridelli C; Goekkurt E; Verhoeven D; Szczesna A; Feurer M; Milanowski J; Germonpre P; Lena H; Atanackovic D; Krzakowski M; Hicking C; Straub J; Picard M; Schuette W; O'Byrne K
Ann Oncol; 2015 Aug; 26(8):1734-40. PubMed ID: 25939894
[TBL] [Abstract][Full Text] [Related]
5. Cisplatin, 5-fluorouracil, and cetuximab (PFE) with or without cilengitide in recurrent/metastatic squamous cell carcinoma of the head and neck: results of the randomized phase I/II ADVANTAGE trial (phase II part).
Vermorken JB; Peyrade F; Krauss J; Mesía R; Remenar E; Gauler TC; Keilholz U; Delord JP; Schafhausen P; Erfán J; Brümmendorf TH; Iglesias L; Bethe U; Hicking C; Clement PM
Ann Oncol; 2014 Mar; 25(3):682-688. PubMed ID: 24567516
[TBL] [Abstract][Full Text] [Related]
6. Cetuximab therapy in head and neck cancer: immune modulation with interleukin-12 and other natural killer cell-activating cytokines.
Luedke E; Jaime-Ramirez AC; Bhave N; Roda J; Choudhary MM; Kumar B; Teknos TN; Carson WE
Surgery; 2012 Sep; 152(3):431-40. PubMed ID: 22770960
[TBL] [Abstract][Full Text] [Related]
7. Reduced proliferation and colony formation of head and neck squamous cell carcinoma (HNSCC) after dual targeting of EGFR and hedgehog pathways.
Liebig H; Günther G; Kolb M; Mozet C; Boehm A; Dietz A; Wichmann G
Cancer Chemother Pharmacol; 2017 Feb; 79(2):411-420. PubMed ID: 28110457
[TBL] [Abstract][Full Text] [Related]
8. A comparative assessment of the effects of integrin inhibitor cilengitide on primary culture of head and neck squamous cell carcinoma (HNSCC) and HNSCC cell lines.
Zhang L; Gülses A; Purcz N; Weimer J; Wiltfang J; Açil Y
Clin Transl Oncol; 2019 Aug; 21(8):1052-1060. PubMed ID: 30632010
[TBL] [Abstract][Full Text] [Related]
9. Combined effects of lapatinib and cisplatin on colony formation of head and neck squamous cell carcinoma.
Schrader C; Boehm A; Reiche A; Dietz A; Mozet C; Wichmann G
Anticancer Res; 2012 Aug; 32(8):3191-9. PubMed ID: 22843892
[TBL] [Abstract][Full Text] [Related]
10. Interleukin-1 alpha increases anti-tumor efficacy of cetuximab in head and neck squamous cell carcinoma.
Espinosa-Cotton M; Rodman Iii SN; Ross KA; Jensen IJ; Sangodeyi-Miller K; McLaren AJ; Dahl RA; Gibson-Corley KN; Koch AT; Fu YX; Badovinac VP; Laux D; Narasimhan B; Simons AL
J Immunother Cancer; 2019 Mar; 7(1):79. PubMed ID: 30890189
[TBL] [Abstract][Full Text] [Related]
11. Simvastatin suppresses head and neck squamous cell carcinoma ex vivo and enhances the cytostatic effects of chemotherapeutics.
Stoehr M; Mozet C; Boehm A; Aigner A; Dietz A; Wichmann G
Cancer Chemother Pharmacol; 2014 Apr; 73(4):827-37. PubMed ID: 24562588
[TBL] [Abstract][Full Text] [Related]
12. Schedule-dependent interaction between temsirolimus and cetuximab in head and neck cancer: a preclinical study.
Lattanzio L; Milano G; Monteverde M; Tonissi F; Vivenza D; Merlano M; Lo Nigro C
Anticancer Drugs; 2016 Jul; 27(6):533-9. PubMed ID: 26982238
[TBL] [Abstract][Full Text] [Related]
13. Cetuximab sensitivity of head and neck squamous cell carcinoma xenografts is associated with treatment-induced reduction in EGFR, pEGFR, and pSrc.
Jedlinski A; Garvin S; Johansson AC; Edqvist PH; Ponten F; Roberg K
J Oral Pathol Med; 2017 Oct; 46(9):717-724. PubMed ID: 28036101
[TBL] [Abstract][Full Text] [Related]
14. IL6 is associated with response to dasatinib and cetuximab: Phase II clinical trial with mechanistic correlatives in cetuximab-resistant head and neck cancer.
Stabile LP; Egloff AM; Gibson MK; Gooding WE; Ohr J; Zhou P; Rothenberger NJ; Wang L; Geiger JL; Flaherty JT; Grandis JR; Bauman JE
Oral Oncol; 2017 Jun; 69():38-45. PubMed ID: 28559019
[TBL] [Abstract][Full Text] [Related]
15. Phase II clinical study of valproic acid plus cisplatin and cetuximab in recurrent and/or metastatic squamous cell carcinoma of Head and Neck-V-CHANCE trial.
Caponigro F; Di Gennaro E; Ionna F; Longo F; Aversa C; Pavone E; Maglione MG; Di Marzo M; Muto P; Cavalcanti E; Petrillo A; Sandomenico F; Maiolino P; D'Aniello R; Botti G; De Cecio R; Losito NS; Scala S; Trotta A; Zotti AI; Bruzzese F; Daponte A; Calogero E; Montano M; Pontone M; De Feo G; Perri F; Budillon A
BMC Cancer; 2016 Nov; 16(1):918. PubMed ID: 27884140
[TBL] [Abstract][Full Text] [Related]
16. ASCT2 (SLC1A5) is an EGFR-associated protein that can be co-targeted by cetuximab to sensitize cancer cells to ROS-induced apoptosis.
Lu H; Li X; Lu Y; Qiu S; Fan Z
Cancer Lett; 2016 Oct; 381(1):23-30. PubMed ID: 27450723
[TBL] [Abstract][Full Text] [Related]
17. An exploratory, open-label, randomized, multicenter study to investigate the pharmacodynamics of a glycoengineered antibody (imgatuzumab) and cetuximab in patients with operable head and neck squamous cell carcinoma.
Temam S; Spicer J; Farzaneh F; Soria JC; Oppenheim D; McGurk M; Hollebecque A; Sarini J; Hussain K; Soehrman Brossard S; Manenti L; Evers S; Delmar P; Di Scala L; Mancao C; Feuerhake F; Andries L; Ott MG; Passioukov A; Delord JP
Ann Oncol; 2017 Nov; 28(11):2827-2835. PubMed ID: 28950289
[TBL] [Abstract][Full Text] [Related]
18. HER3 Targeting Sensitizes HNSCC to Cetuximab by Reducing HER3 Activity and HER2/HER3 Dimerization: Evidence from Cell Line and Patient-Derived Xenograft Models.
Wang D; Qian G; Zhang H; Magliocca KR; Nannapaneni S; Amin AR; Rossi M; Patel M; El-Deiry M; Wadsworth JT; Chen Z; Khuri FR; Shin DM; Saba NF; Chen ZG
Clin Cancer Res; 2017 Feb; 23(3):677-686. PubMed ID: 27358485
[TBL] [Abstract][Full Text] [Related]
19. Cytokine Profiles of Head and Neck Squamous Cell Carcinoma Undergoing Dual Immunotherapy With Cetuximab and Pembrolizumab Identify Interferon Gamma-Induced Protein 10 as Novel Biomarker.
Berszin M; Michaelides I; Siemert J; Röhl L; Wellhausen J; Wald T; Bohr C; Künzel J; Gradistanac T; Dietz A; Zebralla V; Pirlich M; Wiegand S; Wichmann G
Front Oncol; 2022; 12():795277. PubMed ID: 35296001
[TBL] [Abstract][Full Text] [Related]
20. Simultaneous β1 integrin-EGFR targeting and radiosensitization of human head and neck cancer.
Eke I; Zscheppang K; Dickreuter E; Hickmann L; Mazzeo E; Unger K; Krause M; Cordes N
J Natl Cancer Inst; 2015 Feb; 107(2):. PubMed ID: 25663685
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
